07:00 , Jul 30, 2015 |  BC Innovations  |  Targets & Mechanisms

Muscling in on atherosclerosis

A finding from the University of Virginia overturning assumptions about the biology of atherosclerotic plaques could prompt companies to rethink their therapeutic strategies for the disease. Using a series of...
07:00 , Jun 12, 2014 |  BC Innovations  |  Targets & Mechanisms

Stromal uncertainties in pancreatic cancer

Despite the clear rationale for using hedgehog inhibitors in pancreatic cancer-they deplete the stroma to improve chemotherapy delivery-clinical results have been disappointing. New data suggest that the large amounts of stroma surrounding some pancreatic cancers...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in mice and patients suggest depleting tumor stroma and...
07:00 , Apr 3, 2014 |  BC Innovations  |  Targets & Mechanisms

Narrowing down graft stenosis

One of the dominant problems after coronary artery bypass graft surgery is hyperplastic growth inside the transplanted blood vessel that can lead to stenosis. Now, a team at the NIH 's National Heart, Lung, and...
08:00 , Dec 5, 2013 |  BC Innovations  |  Cover Story

Targeting fibrotic integrin

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA) Mouse studies suggest a polyethylene glycol formulation of docetaxel conjugated to acetylated...
07:00 , Aug 29, 2013 |  BC Innovations  |  Targets & Mechanisms

Going stromal with docetaxel

Abraxane nab-paclitaxel is the model example of how an old microtubule-stabilizing chemotherapy can be revitalized through a new nanoparticle formulation. Now, Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease a, Actin 2, smooth muscle, aorta (ACTA2) Genetic studies suggest that a heterozygous ACTA2 mutation could be a...